BAP1 and nonpapillary renal cell carcinoma: Interestingly, we only identified PBRM1 variants in the nonmetastatic ccRCC group (27%); on the contrary, a higher BAP1 prevalence in the metastatic ccRCC group (24% vs. 10%).